Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with severe acute malnutrition among children aged 2 to 23 months presenting with diarrhoea in urban hospitals in Bangladesh.

Journal of health, population, and nutrition·2026
Same author

Survey to evaluate clinical benefits and acceptance in international tele-intensive care unit collaboration.

BMC research notes·2026
Same author

Cytokine Toxicity and Bacterial Dysbiosis in Chemotherapy- and/or Radiotherapy-Induced Oral Mucositis: Pathophysiological Mechanisms and Therapeutic Interventions.

Life (Basel, Switzerland)·2026
Same author

Evaluation of an oral Beta-caryophyllene Indena Phytosome<sup>®</sup> for the treatment of pain and inflammation in interstitial cystitis.

Clinical hemorheology and microcirculation·2026
Same author

Correction: Dyminski Parente Ribeiro et al. Minimally-Invasive Imaging of Sublingual Vessels-A New Method to Study Microvascular Changes in Mice. <i>Life</i> 2025, <i>15</i>, 1478.

Life (Basel, Switzerland)·2026
Same author

Mechanistic insights into postoperative delirium using untargeted high-throughput proteomics in elderly patients - a case-control study.

Scientific reports·2026

Related Experiment Videos

Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.

Jürgen Birnbaum1, Claudia D Spies, Edda Klotz

  • 1Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Charité Virchow-Klinikum, Charité-University Medicine, Berlin, Germany. juergen.birnbaum@charite.de

Renal Failure
|May 15, 2007
PubMed
Summary

Adding iloprost to heparin during continuous renal replacement therapy (CRRT) significantly extended filter life and reduced platelet loss in critically ill patients. This pilot study suggests a potential benefit for CRRT efficacy.

Related Experiment Videos

Area of Science:

  • Nephrology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Continuous renal replacement therapy (CRRT) is vital for critically ill patients with organ dysfunction.
  • Anticoagulation is essential for CRRT but can lead to complications.
  • Heparin is a common anticoagulant, but its efficacy and safety in CRRT can be limited.

Purpose of the Study:

  • To compare the efficacy of heparin anticoagulation with and without iloprost during CRRT.
  • To evaluate the impact of iloprost on filter run time and filter efficiency.
  • To assess the effect on platelet counts and bleeding complications.

Main Methods:

  • Prospective, randomized, controlled pilot study in an intensive care unit.
  • 20 critically ill patients requiring CRRT were divided into two groups: heparin alone vs. heparin plus iloprost.
  • Activated partial thromboplastin time (aPTT) was maintained between 40-50 seconds; observation up to 7 days.

Main Results:

  • Iloprost significantly prolonged median filter run time (14 hours vs. 10 hours, p=0.004).
  • Iloprost attenuated the decrease in platelet count (p=0.012).
  • No significant difference in hemofiltration efficiency or bleeding complications between groups.

Conclusions:

  • Iloprost, when added to heparin, prolongs filter lifespan during continuous veno-venous hemofiltration (CVVH).
  • Iloprost mitigates the decline in platelet count associated with CRRT.
  • This combination may improve CRRT management in critically ill patients.